Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Ye

Showing results (551-560 of 563) with videos related to

Pageof 57
Sort By:
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature|August 9, 2023
R-loop-dependent promoter-proximal termination ensures genome stabilityCongling Xu, Chengyu Li, Jiwei Chen, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
The Journal of Experimental Medicine|July 5, 2013
Altered protein prenylation in Sertoli cells is associated with adult infertility resulting from childhood mumps infectionXiu-Xing Wang, Pu Ying, Fan Diao, et al.
EMBO Reports|March 2, 2018
SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancerXiu-Fei Chen, Meng-Xin Tian, Ren-Qiang Sun, et al.
Journal of Hepatology|March 16, 2022
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesisRenqiang Sun, Zhiyong Zhang, Ruoxuan Bao, et al.
Cell Reports|November 8, 2018
SNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage ResponseLei-Lei Chen, Huai-Peng Lin, Wen-Jie Zhou, et al.
Cancer Immunology Research|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast CancerKyung-Min Lee, Chang-Ching Lin, Alberto Servetto, et al.
Cell Reports|July 16, 2020
The Zscan4-Tet2 Transcription Nexus Regulates Metabolic Rewiring and Enhances Proteostasis to Promote ReprogrammingZhou-Li Cheng, Meng-Li Zhang, Huai-Peng Lin, et al.
Ebiomedicine|June 27, 2025
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerMaxwell R Lloyd, Rosario Chica-Parrado, Caroline M Weipert, et al.
Pageof 57

Showing results (551-560 of 563) with videos related to

Sort By:
Pageof 57
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature|August 9, 2023
R-loop-dependent promoter-proximal termination ensures genome stabilityCongling Xu, Chengyu Li, Jiwei Chen, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
The Journal of Experimental Medicine|July 5, 2013
Altered protein prenylation in Sertoli cells is associated with adult infertility resulting from childhood mumps infectionXiu-Xing Wang, Pu Ying, Fan Diao, et al.
EMBO Reports|March 2, 2018
SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancerXiu-Fei Chen, Meng-Xin Tian, Ren-Qiang Sun, et al.
Journal of Hepatology|March 16, 2022
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesisRenqiang Sun, Zhiyong Zhang, Ruoxuan Bao, et al.
Cell Reports|November 8, 2018
SNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage ResponseLei-Lei Chen, Huai-Peng Lin, Wen-Jie Zhou, et al.
Cancer Immunology Research|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast CancerKyung-Min Lee, Chang-Ching Lin, Alberto Servetto, et al.
Cell Reports|July 16, 2020
The Zscan4-Tet2 Transcription Nexus Regulates Metabolic Rewiring and Enhances Proteostasis to Promote ReprogrammingZhou-Li Cheng, Meng-Li Zhang, Huai-Peng Lin, et al.
Ebiomedicine|June 27, 2025
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerMaxwell R Lloyd, Rosario Chica-Parrado, Caroline M Weipert, et al.
Pageof 57